Vismodegib resistance in basal cell carcinoma: not a smooth fit

Cancer Cell
Todd W Ridky, George Cotsarelis

Abstract

In this issue of Cancer Cell, two complementary papers by Atwood and colleagues and Sharpe and colleagues show that basal cell carcinomas resistant to the Smoothened (SMO) inhibitor vismodegib frequently harbor SMO mutations that limit drug binding, with mutations at some sites also increasing basal SMO activity.

Citations

Oct 2, 2015·Cancers·Daniel L Suzman, Emmanuel S Antonarakis
Sep 4, 2016·Trends in Molecular Medicine·Davide D'Amico, Gianluca Canettieri
Sep 17, 2016·Expert Review of Anticancer Therapy·Nicholas J CollierJohn T Lear
Jun 3, 2017·Molecular Carcinogenesis·Anshika BakshiMohammad Athar
Mar 27, 2019·Future Medicinal Chemistry·Christian Espinosa-BustosCristian O Salas
Dec 22, 2016·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·Lawrence FeigenbaumRajiv I Nijhawan
May 25, 2016·Cancer Control : Journal of the Moffitt Cancer Center·Kyle F Cox, Curtis E Margo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Carcinoma, Basal Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.